+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 686 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.

Age: 18Years +All GendersPhase 2Phase 3
88 locations
C

Actively Recruiting

Researchers are evaluating two methods for making occlusal splints night guards in adults diagnosed with bruxism, which includes teeth grinding and clenching. This randomized clinical trial aims to compare a 3D-printed photopolymer resin splint Voco V-Print with a conventional acrylic splint to determine if the newer 3D-printed option offers similar patient satisfaction and durability. The study focuses on adults aged 18 to 25 years with bruxism and temporomandibular disorders. Participants will be randomly assigned to receive either a 3D-printed splint or a conventional acrylic splint, both custom-made and adjusted as needed. They will be instructed to wear their assigned splint during sleep for three months, following standardized care and use instructions. The study includes a follow-up at 3 months to assess outcomes. During the study, patient satisfaction and oral health-related quality of life will be measured using a questionnaire based on the Oral Health Impact Profile OHIP. The splints will also be scanned with 3D technology at the start and after three months to measure wear by comparing volume loss. These assessments will help researchers understand patient experiences and the clinical durability of each splint type over the short-term period.

Age: 18Years - 25YearsAll GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are evaluating the effects of two different voltage settings, 45 V and 60 V, for pulsed radiofrequency PRF treatment applied to the cervical dorsal root ganglion DRG in patients experiencing cervical radicular pain. This condition involves nerve pain radiating from the neck due to nerve root compression, often following inadequate response to conservative treatments. The study aims to compare pain relief and functional improvement between these two PRF voltage groups, while also monitoring any procedure-related side effects. Participants receive PRF treatment targeted at the cervical DRG under fluoroscopic guidance. Both groups undergo a similar procedure involving local anesthesia and sensory stimulation to confirm correct needle placement. The PRF is then applied for 240 seconds at a maximum temperature of 42C, with either 45 V or 60 V applied depending on the assigned group. After the procedure, patients are observed for 60 minutes before discharge. The study uses a randomized, parallel design to compare these two active treatment groups. Participants pain levels are measured using the Numerical Rating Scale NRS, and functional disability is assessed with the Neck Disability Index NDI before treatment and at 3 and 6 months afterward. Researchers also record any adverse events related to the procedure throughout the follow-up period. This allows assessment of both the effectiveness and safety of each voltage setting. The total study duration spans from the initial treatment through the 6-month follow-up assessments.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

This research aims to examine the effects of an 8-week artificial intelligence-based structured exercise program on posture in healthy adults aged 18 to 25 years. Posture is the arrangement of body parts relative to each other, influenced by gravity, muscle tension, and bone structure. The study focuses on common posture disorders in young adults and uses measurements like the craniovertebral angle, thoracic kyphosis, and lumbar lordosis to assess changes. Participants will be randomly assigned to one of two groups. One group will perform exercises guided by an artificial intelligence application called Musclewiki alongside a physiotherapist, practicing three times a week for 8 weeks. The other group will not perform any exercise during this period. Posture measurements will be taken before and after the 8-week program using a mobile app to evaluate angles related to head, shoulder, and spine alignment. During the study, participants will have posture assessments using frontal and lateral images analyzed by the Posture Screen Mobile app. The primary outcome is the change in craniovertebral angle after 8 weeks. Secondary outcomes include changes in thoracic kyphosis and lumbar lordosis angles. The study will monitor participants throughout the 8-week period, with evaluations before and after the intervention to understand the exercise programs impact on posture.

Age: 18Years - 25YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.

Age: 18Years +All GendersPhase 3
106 locations
E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
S

Actively Recruiting

Researchers are studying calderasib alone and in combination with cetuximab to treat advanced solid tumors in people with the KRAS G12C mutation. The study aims to find out how many patients respond to these treatments and to evaluate their safety and tolerability. This phase 2 trial is tumor-agnostic, meaning it includes various solid tumors except colorectal cancer that have progressed despite standard treatment. Participants receive calderasib by mouth, either alone or with cetuximab given by intravenous infusion every two weeks. There is no set maximum number of treatment cycles, and participants continue until they meet criteria to stop treatment. The study is randomized and open-label, comparing the two treatment approaches in parallel groups. During the study, participants will be monitored for tumor response, adverse events, and reasons for discontinuing treatment over about 76 months. Researchers will assess progression-free survival, duration of response, and overall survival. Safety evaluations and regular clinical visits will support ongoing monitoring throughout the trial.

Age: 18Years +All GendersPhase 2
72 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are investigating new treatment options for extensive-stage small cell lung cancer ES-SCLC, a type of lung cancer that has spread widely within the lungs or to other parts of the body. This study evaluates the combination of two investigational drugs, gocatamig and ifinatamab deruxtecan I-DXd, alongside standard chemotherapy and immunotherapy treatments. The research aims to understand the safety and tolerability of these combined therapies and whether they can reduce or eliminate cancer in participants. Participants in the trial may receive different treatment regimens depending on their prior therapy history. Some will receive gocatamig and I-DXd together in maintenance after standard chemotherapy and immunotherapy, while others will receive these drugs during both induction and maintenance phases. Additional groups will receive combinations including gocatamig, I-DXd, atezolizumab, carboplatin, and etoposide in varying sequences. Treatments are delivered intravenously, and participants continue until disease progression or other criteria require stopping. During the study, participants will have regular assessments including imaging to measure tumor response, safety monitoring for adverse events, and laboratory tests to understand drug levels and immune reactions. Researchers will track side effects, dose-limiting toxicities, and treatment discontinuations over a period of up to about 58 months. The main outcomes include tumor response and safety, with ongoing evaluation of disease control, survival, and drug exposure throughout the study duration.

Age: 18Years +All GendersPhase 1Phase 2
57 locations
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations

1-10 of 686

1